Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotechs Back To “New Normal,” E&Y Reports

This article was originally published in The Pink Sheet Daily

Executive Summary

The annual report issued by Ernst & Young shows that biotech funding and revenues are back to relatively normal levels after a few years of pullback, but 2011 could be a transitional year.

You may also be interested in...

On Building A Better R&D Machine, Part 2: Pfizer’s R&D Chief Mikael Dolsten Talks Partnering Strategy And Accessing Innovation

Since ascending to the top R&D spot at the world’s largest pharmaceutical company, Mikael Dolsten has taken the lead in focusing R&D at Pfizer and optimizing its portfolio. In the second of a two-part interview with "The Pink Sheet" DAILY, Dolsten shares his thoughts on partnering and accessing external opportunities.

Biotechs Need To Be More Differentiated To Succeed, E&Y Reports

The 25th annual Ernst & Young report shows that biotechs have fewer exit strategies than ever and that pre-clinical stage companies still have a hard time finding financing.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts